The clinical application of atorvastatin in patients with small-cell lung cancer with dyslipidemia

ConclusionAtorvastatin added to first-line standard chemotherapy achieved prospective efficacy and manageable safety in SCLC combined dyslipidemia.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research